Oral Idarubicin in the Treatment of Advanced Breast Cancer

References

• Ohashi K., Gillies H. C, Rogers H. J, et al. Pharmacokinetics of Idarubicin (IMI-30): An orally administered anthracycline. Proc 14th Int Congr on Chemother 1986; 328: 18–56
   Google Scholar
• Robert J., Rigal-Huguet F., Hurteloup P. Pharmacokinetics of Idarubicin administered per os in leukemia patients. Proc ECCO 1987; 4: 299
   Google Scholar
• Bastholt L., Dalmark M. Phase II study of Idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep 1987; 71: 451–4
   PubMedGoogle Scholar
• Lionetto R., Pronzato P., Conte P. F, et al. Idarubicin in advanced breast cancer: a phase II study. Cancer Treat Rep 1986; 70: 1439–40
   PubMedGoogle Scholar
• Lopez M., Di Lauro L., Papaldo P., et al. Phase II trial with oral Idarubicin in advanced breast cancer. Invest New Drugs 1986; 4: 3942
   Google Scholar
• Martoni A., Pacciarini M. A, Panutti F. Activity of 4-demeth-oxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 803–6
   PubMedGoogle Scholar
• Hoogstraten B., Fabian C. A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 1979; 2: 101–9
   Google Scholar
• Gundersen S., Kvinnsland S., Klepp O., et al. Weekly Adria-mycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1431–4
   PubMedGoogle Scholar
• Sigurdsson H., Johansson-Terje I., Aspegren K., et al. Weekly-dose doxorubicin (WDA) in advanced breast cancer. Ra-diother Oncol 1986; 7: 133–9
   PubMedGoogle Scholar
• Chlebowski R. T, Paroly W. S, Pugh R. P, et al. Adriamycin given as a weekly schedule without a loading dose: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47–51
   PubMedGoogle Scholar
• Torti F. M, Brestow M. R, Howes A. E, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Int Med 1983; 99: 745–9
   PubMed Web of Science ®Google Scholar
• Weiss A. J, Metter G. E, Fletcher W. S, et al. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 60: 813–22
   PubMedGoogle Scholar
• Krarup-Hansen A., Andersen E., Elbaek K., et al. Phase I study of weekly 4-demethoxydaunorubicin (DMDR) by oral route in patients with solid tumors. Proc ECCO 1987; 4, Abstract 274
   Google Scholar
• World Health Organization. Handbook for reporting results of cancer treatment. WHO, Geneva 1979
   Google Scholar
• Powles T. J, Coombes R. C, Smith J. E, et al. Failure of chemotherapy to prolong survival in a group of patients with meta-static breast cancer. Lancet 1980; l: 580–2
   Google Scholar
• Todd M., Shoag M., Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol 1983; 6: 406–8
   Google Scholar
• Patel J. K, Nemoto T., Vezeridis, et al. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients. Cancer 1986; 57: 567–70
   PubMed Web of Science ®Google Scholar
• Haskell C. M, Sullivan A. Comparative survival in tissue culture of normal and neoplastic human cells exposed to Adria mycin. Cancer Res 1974; 34: 29914
   Google Scholar
• Frei I. E, II, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–94
   PubMed Web of Science ®Google Scholar
• Hryniuk W. M, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 11: 1281–8
   Google Scholar
• Swenerton K. D, Legha S. S, Smith T., et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39: 1552–62
   PubMed Web of Science ®Google Scholar
• Creech R. H, Catalano R. B, Hopson RC. A comparison of standard dose Adriamycin and low dose Adriamycin as primary chemotherapy for metastatic breast cancer. Proc AACR 1980; 21: 142
   Google Scholar
• Carmo-Pereira J., Costa F. O, Henriques E., et al. Advanced breast carcinoma: A comparison of two dose levels of Adriamycin. Proc ASCO 1986; 5: 218
   Google Scholar